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Running title: National Vaccine Adoption Decision-Making Processes
Key Messages:
Decisions to adopt new vaccines are, by nature, political
The main drivers influencing decisions to adopt new vaccines were the 
availability of funding, political prioritisation of vaccination (or the vaccine-
preventable disease) and burden of disease
There was little consideration of the financial implications of adopting a new 
vaccine, nor the feasibility of introduction, prior to the decision
The desire to seize donor funding opportunities may inhibit evidence-informed 
decision-making 
Abstract
As more new and improved vaccines become available, decisions on which to 
adopt into routine programmes become more frequent and complex. This 
qualitative study aimed to explore processes of national decision-making 
around new vaccine adoption and to understand the factors affecting these 
decisions.
Ninety-four key informant interviews were conducted in seven low- and middle-
income countries: Bangladesh, Cameroon, Ethiopia, Guatemala, Kenya, Mali 
and South Africa. Framework analysis was used to explore issues both within 
and between countries.
The underlying driver for adoption decisions in GAVI-eligible countries was the 
desire to seize GAVI windows of opportunity for funding. By contrast, in South 
Africa and Guatemala, non-GAVI-eligible countries, the decision-making 
process was more rooted in internal and political dynamics.
Decisions to adopt new vaccines are, by nature, political. The main drivers 
influencing decisions were the availability of funding, political prioritisation of 
vaccination or the vaccine-preventable disease and the burden of disease. 
Other factors, such as financial sustainability and feasibility of introduction, were 
not as influential. Although GAVI procedures have established more formality in 
decision-making, they have not always resulted in consideration of all relevant 
factors. As familiarity with GAVI procedures has increased, questioning by 
decision-makers about whether a country should apply for funding appeared to 
have diminished. 
This is one of the first studies to empirically investigate national processes of 
new vaccine adoption decision-making using rigorous methods. Our findings 
show that previous decision-making frameworks (developed to guide or study 
national decision-making) bear little resemblance to real-life decisions, which 
are dominated by domestic politics. Understanding the realities of vaccine 
policy decision-making is critical for developing strategies to encourage 
evidence-informed decision-making about new vaccine adoptions. The 
potential for international initiatives to encourage evidence-informed decision-
making should be realised, not assumed.
Introduction
The beginning of the Decade of Vaccines is an exciting time, following 
unprecedented pledged funding to the GAVI Alliance and the ever-increasing 
pace of development of new vaccines (Moszynski, 2011, Moxon and Siegrist, 
2011). However it is also a time for reflection about the challenges ahead and 
problems faced both at country and global levels (Moxon et al., 2011, 
Mahmoud, 2011, Cunliffe and Nakagomi, 2007). 
One of these challenges is how governments decide which vaccines to adopt 
into their national immunisation programme. As new and improved vaccines 
become available, governments must make these decisions more frequently. 
New vaccines are more expensive than traditional ones and some have 
particular logistical, or delivery issues, making adoption decisions ever-more 
complex (Levine et al., 2011, Andrus et al., 2011). At the same time, the role of 
funding institutions such as the GAVI Alliance (GAVI) has led to criticism that 
decisions are taken out of national governments’ hands and calls for the 
encouragement of more national autonomy (Moxon et al., 2011, Zuber et al., 
2011, Mahmoud, 2011). 
Over the past decade, GAVI has become instrumental in providing financial 
support to low- and middle-income countries to introduce new vaccines. Once 
GAVI announces a call for funding proposals, countries wishing to apply must 
express their interest. GAVI requires that countries set up inter-agency 
coordinating committees (ICCs) to coordinate funding applications and 
introduction plans.
Several initiatives aim to encourage countries to adopt new vaccines, to 
generate evidence to support adoption decisions (e.g. Diseases of the Most 
Impoverished project (DOMI) and GAVI’s Accelerated Vaccine Introduction 
Initiative) and to support evidence-informed vaccine decision-making (e.g. 
ProVac, SIVAC, the Hib Initiative) (Levine, 2004, Program for Appropriate 
Technology in Health (PATH) et al., 2003, Acosta et al., 2004, Andrus et al., 
2007, Senouci et al., 2010, Hajjeh et al., 2010). However a recent systematic 
review concluded that little was known about decision-making processes, since 
few studies had explored them and those that did tended to be 
methodologically weak (Burchett et al., 2011).
Numerous frameworks have been developed to either support or study 
decision-making processes; a recent systematic review identified 21 unique 
frameworks, with more published since then (Burchett et al., 2011, Levine et al., 
2010). Most frameworks lack information about how they have been developed 
or whether they have been tested or validated, making it difficult to assess their 
quality. There is a need to improve our understanding of how adoption 
decisions are made, in order to better support countries in making the right 
decisions for their own situation (Wenger et al., 1999, Piso and Wild, 2009, 
Munira and Fritzen, 2007). This study aimed to explore the process of vaccine 
adoption decision-making in low- and middle-income countries and to 
understand which factors are most critical.
Methods
This qualitative study involved semi-structured interviews with key informants in 
seven low- and middle-income countries; Bangladesh, Cameroon, Ethiopia, 
Guatemala, Kenya, Mali and South Africa. Countries were purposively selected 
to cover both GAVI-eligible and non-GAVI-eligible (as donors may influence 
decision-making processes), different health system strengths, various speeds 
of vaccine adoption and different geographical regions (Table 1). 
Table 1: Demographic and economic statistics of the case study countries 
CountryPopulation (million)
20091Under five mortality rate1
2009GNI per capita (US$)1
2009Total expenditure on health as % of GDP1,2
2009Eligible for GAVI 
support3 
2011Bangladesh
162 52 580 3.4% Yes
Cameroon 19 154 1,190 5.6% Yes
Ethiopia   79* 104 330 4.3% Yes
Guatemal
a
14 40 2,650 7.1% No
Kenya 40 89 760 4.3% Yes
Mali   15** 191 460 5.6% Yes
S o u t h 
Africa
49 62 5,760 8.5% No
1  ADDIN EN.CITE <EndNote><Cite><Author>Wor ld Bank</Author><Year>2011</Year><RecNum>58</
RecNum><DisplayText>(World Bank, 2011)</DisplayText><record><rec-number>58</rec-number><foreign-keys><key 
app="EN" db-id="fw0tp0r9tertx0e2et452r9ttpwpp2z2xfwt">58</key></foreign-keys><ref-type name="Web Page">12</ref-
type><contributors><authors><author>World Bank,</author></authors></contributors><titles><title>Data: Indicators</title></
titles><number>01/07/2011</number><dates><year>2011</year></dates><urls><related-urls><url>http://data.worldbank.org/
indicator</url></related-urls></urls></record></Cite></EndNote>( HYPERLINK  \l "_ENREF_38" \o "World Bank, 2011 #58" 
World Bank, 2011) except where stated otherwise
2 Total health expenditure is the sum of public and private health expenditure
3  ADDIN EN.CITE <EndNote><Cite><Author>GAVI All iance</Author><Year>2011</Year><RecNum>62</
RecNum><DisplayText>(GAVI Alliance, 2011)</DisplayText><record><rec-number>62</rec-number><foreign-keys><key 
app="EN" db-id="fw0tp0r9tertx0e2et452r9ttpwpp2z2xfwt">62</key></foreign-keys><ref-type name="Web Page">12</ref-
type><contributors><authors><author>GAVI Alliance,</author></authors></contributors><titles><title>Eligible countries</
title></titles><number>13th July 2011</number><dates><year>2011</year></dates><urls><related-urls><url>http://
www.gavialliance.org/support/who/eligible/index.php</url></related-urls></urls></record></Cite></EndNote>( HYPERLINK  \l 
"_ENREF_11" \o "GAVI Alliance, 2011 #62" GAVI Alliance, 2011)
*  ADDIN EN.CITE <EndNote><Cite><Author>Central Statistical Agency</Author><Year>2009</Year><RecNum>65</
RecNum><DisplayText>(Central Statistical Agency, 2009)</DisplayText><record><rec-number>65</rec-number><foreign-
keys><key app="EN" db-id="fw0tp0r9tertx0e2et452r9ttpwpp2z2xfwt">65</key></foreign-keys><ref-type name="Report">27</
r ef- type> < contr i butor s> < author s> < author > Centr al Stati s ti cal Agency, Ethiopia< /author > < /author s> < /
contributors><titles><title>Statistical Abstract Ethiopia</title></titles><dates><year>2009</year></dates><urls></urls></
record></Cite></EndNote>( HYPERLINK  \l "_ENREF_8" \o "Central Statistical Agency, 2009 #65" Central Statistical Agency, 
2009)
**  ADDIN EN.CITE <EndNote><Cite><Author>Institut National de la Statistique</Author><Year>2011</Year><RecNum>64</
RecNum><DisplayText>(Institut National de la Statistique, 2011)</DisplayText><record><rec-number>64</rec-
number><foreign-keys><key app="EN" db-id="fw0tp0r9tertx0e2et452r9ttpwpp2z2xfwt">64</key></foreign-keys><ref-type 
name="Web Page">12</ref-type><contributors><authors><author>Institut National de la Statistique, Republique du Mali</
author></authors></contr ibutors><titles><title>Indicateurs Recents</ti tle></ti tles><number>13th July 2011</
number><dates><year>2011</year></dates><urls><related-urls><url>http://instat.gov.ml/</url></related-urls></urls></
record></Cite></EndNote>( HYPERLINK  \l "_ENREF_15" \o "Institut National de la Statistique, 2011 #64" Institut National de la 
Statistique, 2011)
In all case study countries the Expanded Programme on Immunisation (EPI) 
offered vaccination free of charge at the point of delivery. All countries had 
adopted a new vaccine within the last three years. Table 2 shows vaccine 
coverage rates and dates of new vaccine introductions. Some countries were 
early adopters, while others had more mixed patterns. All countries, apart from 
South Africa, had a specific line item in their national health budget for vaccines.
Table 2: Vaccination coverage and recent vaccine introductions
Country2010 estimated DTP3 coverage1Rotavirus vaccine 
introduction2Pneumococcal vaccine introduction2Hib vaccine 
introduction2Other 
previous vaccine introductions2Bangladesh
89% -- Planned
2013
2009 Hepatitis B 
(2003)
Cameroon 84% Planned 
2013
2011 2009 Yellow 
fever 
(2004), 
Hepatitis 
B (2005)
Ethiopia 86% Planned 
2012
2011 2007 Hepatitis 
B (2007)
Guatemal
a
94% 2010 Planned 
2013
2005 Influenza 
(2007)
Hepatitis B 
birth dose 
(2010)
Kenya 83% Planned 
2013
2011 2001 Hepatitis 
B (2001)
Mali 92% Planned 
2012
2011 2005 Meningitis 
A (2011), 
Yellow 
fever 
(2001), 
Hepatitis B 
(2002)
South 
Africa
91% 2009 2009 1999 Intravenou
s polio 
vaccine 
(2009), 
Hepatitis B 
(1995)
1 ADDIN EN.CITE <EndNote><Cite><Author>World Health Organization</
Author><Year>2011</Year><RecNum>63</RecNum><DisplayText>(World Health 
Organization, 2011b)</DisplayText><record><rec-number>63</rec-number><foreign-
keys><key app="EN" db-id="fw0tp0r9tertx0e2et452r9ttpwpp2z2xfwt">63</key></
foreign-keys><ref-type name="Web Page">12</ref-
type><contributors><authors><author>World Health Organization,</author></authors></
contributors><titles><title>WHO/UNICEF estimates of national immunization coverage</
title></titles><number>13th July 2011</number><dates><year>2011</year></
dates><label>http://www.who.int/immunization_monitoring/routine/
immunization_coverage/en/index4.html</label><urls></urls></record></Cite></
EndNote>( HYPERLINK  \l "_ENREF_41" \o "World Health Organization, 2011 #63" World 
Health Organization, 2011b)
2 ADDIN EN.CITE <EndNote><Cite><Author>World Health Organization</
Author><Year>2011</Year><RecNum>59</RecNum><DisplayText>(World Health 
Organization, 2011a)</DisplayText><record><rec-number>59</rec-number><foreign-
keys><key app="EN" db-id="fw0tp0r9tertx0e2et452r9ttpwpp2z2xfwt">59</key></
foreign-keys><ref-type name="Online Database">45</ref-
type><contributors><authors><author>World Health Organization,</author></authors></
contributors><titles><title>WHO Vaccine Preventable Diseases Monitoring System: 
2011 Global Summary</title></titles><dates><year>2011</year><pub-
dates><date>01/07/2011</date></pub-dates></dates><urls><related-urls><url>http://
apps.who.int/immunization_monitoring/en/globalsummary/countryprofileselect.cfm</
url></related-urls></urls></record></Cite></EndNote>( HYPERLINK  \l "_ENREF_40" \o 
"World Health Organization, 2011 #59" World Health Organization, 2011a)
Interviewees were purposively selected if they were involved in, or 
knowledgeable about, the process of vaccine adoption decision-making. 
Interviewees included EPI officers, Ministry of Health staff, World Health 
Organisation (WHO) and United National Children fund (UNICEF) country 
representatives, academics, members of immunisation advisory committees 
and ICCs and other key stakeholders. In total, 94 key informants were 
interviewed; 11-15 per country.
The interview topic guide was based on a previously-devised decision-making 
framework (see table 3) (Burchett et al., 2011). Interviews focused on the most 
recent adoptions or those expected in the near future: mainly pneumococcal 
and rotavirus vaccines, but also haemophilus influenzae type b (Hib), human 
papillomavirus (HPV), measles second dose, rubella, hepatitis B birth dose and 
meningococcal A vaccines. 
Interviews were conducted between October 2010 and March 2011, mostly by a 
national researcher and LSHTM team member. Most interviews were conducted 
in English. In Guatemala, interviews were in Spanish, in French in Mali, in 
French and English in Cameroon and one interview was conducted in Amharic 
in Ethiopia. Prior to interviews, the aim of the study was explained and an 
information sheet provided. After discussing any questions or concerns, 
interviewees signed a consent form. Where permitted and possible, interviews 
were recorded, transcribed and, if necessary, translated into English. When they 
were not recorded, notes were taken and typed up in detail afterwards. 
Table 3: Framework of New Vaccine Adoption Decision-Making 
Category Criteria
The importance of the health problem
Burden of disease 
(e.g. prevalence)
Political priority
Costs of disease
Perceptions of importance 
(e.g. perceived severity)
Other
Vaccine characteristics
Efficacy/effectiveness
Vaccine safety
Delivery issues 
(e.g. vaccine schedule)
Other characteristics
Programmatic considerations
Feasibility
Vaccine supply
Acceptability Acceptability of vaccine
Accessibility, equity and ethics Accessibility, equity and ethics
Financial/ economic issues
Economic evaluation
Incremental costs
Funding sources
Vaccine price
Financial sustainability
Other 
(including affordability)
Ethical approval was obtained in each country and from LSHTM. Framework 
analysis was used to explore the data (Ritchie and Spencer, 1994). An initial, 
broad coding framework was drawn up based on a preliminary assessment of 
the interview transcripts and the previously-developed decision-making 
framework (Burchett et al., 2011). These codes were applied to each country’s 
data. A meeting was held where all collaborators identified key issues arising 
from the data and further refining the coding framework. The revised framework 
was subsequently applied to the transcripts by charting and mapping the codes, 
first by country and then across countries. The software ‘Open Code’ was used 
(Umea University, 2011). 
Findings
Decision-Making Process
Actors Involved
In all countries, only a small number of actors were directly involved in 
decisions to adopt new vaccines. As would be expected, national Ministry of 
Health officials played a central role in all countries. 
In Guatemala and South Africa, smaller groups than in the GAVI-eligible 
countries were directly involved in decision-making. In these two countries, 
interviewees noted that recent adoption decisions (for rotavirus vaccine and 
pneumococcal and rotavirus vaccines, respectively) came as a surprise, 
highlighting the fact that many officials were unaware of discussions around the 
decision until it was announced. The Minister of Health was particularly central 
to these decisions, along with one or two advisors. In both countries, the EPI 
teams within the Ministry of Health were not involved in the decision-making. 
This contrasted starkly to the situation in the GAVI-eligible countries, where EPI 
managers and their staff played a central role. 
Ministers of Health also had influence in GAVI-eligible countries, with many 
interviewees noting their support or passion for child health and vaccination. 
Some Ministers were perceived as championing vaccination because of their 
professional background (e.g. paediatrics) or their gender (female); others 
simply because vaccination appealed for political reasons. In Ethiopia, the 
Minister (who had previously been a GAVI board member) insisted that the 
country apply to introduce the rotavirus vaccine earlier than the technical team 
had planned, whilst in Kenya interviewees reported that the Minister had been 
lobbying at global levels for access to vaccines at reduced prices. 
"The minister is extremely supportive of the vaccination programme. The 
events ...which mobilise the minister most are to do with EPI....therefore 
at political level, it is clearly important.” 004, Cameroon
Despite being considered good practice, only South Africa had an active 
technical advisory committee for immunisation. Their National Advisory Group 
on Immunisation (NAGI) was a strong and influential group of prominent 
academics and clinicians. Although influential in the build-up of the evidence, it 
was not directly involved throughout the decision-making process. In 
Guatemala, the National Advisory Committee on Immunisation Practices (ACIP) 
had been inactive for several years and did not participate in the rotavirus 
vaccine adoption decision. In GAVI-eligible countries, no advisory committees 
were operational in the run-up to the decisions studied. 
WHO was considered an important stakeholder, particularly in GAVI-eligible 
countries, providing information about future vaccine developments, technical 
support, financing surveillance and organising workshops to assist the 
preparation of GAVI applications. 
Ministry of Finance involvement in decisions to apply for GAVI funding was not 
always clear. Some stated that finance officials were not involved, whilst others 
felt that they had been consulted. It was unclear at what stage they were 
brought into the decision-making process and whether they had any influence 
or were merely there to sign the GAVI application. In some countries, 
discussions with the Ministry of Finance commenced after GAVI funding had 
been approved. South Africa was unique in that interviewees reported the 
critical involvement and leadership of a Ministry of Finance health official (with a 
public health background). In no other country was Treasury pushing for the 
adoption of new vaccines.
Researchers and clinicians (notably paediatricians and National Paediatric 
Societies) were involved in advocacy in many countries, although their 
influence varied. National actors with global links seemed to have more 
influence than those without international involvement. 
Sub-national actors were not involved in national vaccine adoption decision-
making in any of the countries.
Pharmaceutical companies played a key role in GAVI non-eligible countries, 
with interviewees reporting that their lobbying influenced decision-making. In 
GAVI-eligible countries, although some interviewees mentioned contact with 
pharmaceutical companies, these were not felt to have influenced decisions.
Cues to Action
For GAVI-eligible countries, GAVI funding calls were, understandably, a key 
cue. However it was by no means the only factor triggering the decision-making 
process. In Kenya, Ethiopia and Mali, discussions about the pneumococcal 
vaccine preceded the GAVI call, with the adoption of the pentavalent vaccine 
leading to consideration of additional ways to reduce childhood pneumonia. In 
Bangladesh, advocacy by the Hib Initiative (a GAVI-funded consortium with the 
mandate of accelerating evidence-based decision-making for Hib vaccine) was 
cited as a cue to action for its adoption, with the organisation of a regional 
workshop and a national consultative meeting. A question about the 
pneumococcal vaccine was posed by a visiting British member of parliament to 
their Bangladeshi counterpart, who subsequently raised the topic in 
parliament. This parliamentary debate raised awareness about the vaccine 
and may have led to Bangladesh’s GAVI application for pneumococcal vaccine 
in May 2011.
International and national meetings (e.g. World Health Assemblies and WHO 
regional meetings) were often noted as key events, briefing country 
stakeholders about new vaccine developments and providing lobbying 
opportunities. Advocacy activities by international agencies, such as the WHO, 
played a key role in setting the agenda at country level and in supporting the 
decision-making process. 
National advocacy activities also helped to get new vaccines onto the decision-
making agenda. For example in Mali, the directors of two research institutions, 
the Malian research institute, the Centre for Vaccine Development (CVD) and 
the US CVD, met the president of the Republic to present disease burden 
evidence and lobby for the introduction of the Hib vaccine, leading to his 
executive decision to adopt the vaccine.
In both Guatemala and South Africa, diarrhoea outbreaks were key triggers for 
rotavirus vaccine adoption decisions. In both cases the outbreaks gained 
substantial media attention leading to pressure on the Minister of Health to be 
seen to take action. In South Africa, pivotal vaccine efficacy studies had been 
conducted which, combined with subsequent advocacy from academics, were 
considered the starting point of discussions about pneumococcal and rotavirus 
vaccine adoption.
Procedures
In both South Africa and Guatemala, the decision-making process for recent 
adoptions deviated from their formal processes. In South Africa, only the first two 
stages of the process happened as expected. The advisory group (NAGI) 
reviewed evidence for pneumococcal and rotavirus vaccines in 2007 and made 
a recommendation to the Department of Health. The EPI team then made a 
submission to the Minister to adopt the pneumococcal vaccine only, with plans 
to introduce it in 2010. Normally, the submission would then go to the National 
Health Council who would decide whether to approve the adoption. In reality, it 
seems that following a period with no developments, ad hoc meetings were 
held by the Minister, her advisors, the Ministry of Finance health official and the 
chair of the NAGI. A few months later, at the World Health Assembly in 2008, the 
Minister announced plans to adopt both pneumococcal and rotavirus vaccines 
within three months.
“It appeared to come from nowhere…and it really took everyone by 
surprise because…certain people were talking about it, thinking about it 
but the consensus was that it was something that we would like to do but 
that it was just too costly at that stage and then...it was announced by the 
Minister in Geneva at the WHA…and basically took everyone by 
surprise…” 004, South Africa 
In Guatemala, the decision to introduce rotavirus vaccine was also a surprise to 
interviewees and was generally considered to be a ‘quick’ decision. Although in 
2006-7, the advisory committee (ACIP) had started discussing the vaccine, this 
was postponed with the launch of a measles and rubella catch-up campaign. In 
July 2009, EPI staff were asked to submit a funding request but declined as they 
felt the programme was not ready for an introduction. However in December 
2009, they were told that the vaccine would shortly be introduced. The normal 
process, where the EPI team meets with technical experts to discuss the 
advantages and disadvantages of adopting a new vaccine, was not followed. 
In the GAVI-eligible countries, the requirements for GAVI funding applications 
led to more structured decision-making procedures. In some (e.g. Ethiopia) 
there were several discussions (e.g. during ICC meetings) about the 
pneumococcal vaccine prior to the expression of interest in applying for funding. 
However in others (e.g. Cameroon, Kenya and Bangladesh) there was less 
discussion as the need for the vaccine was well accepted. Although the ICC 
could be a forum for discussions, it mostly remained a technical body that was 
not the locus of the decision. 
In Bangladesh the National Committee on Immunisation Practices (NCIP) had a 
decision-making function and several interviewees assumed this committee 
had discussed whether new vaccines should be adopted. However when 
committee members were interviewed, they did not report participating in 
meetings or discussions. In all countries, actors peripheral to the decision-
making process often assumed that the process was more formal, structured 
and evidence-based and involving a wider range of actors than seemed to be 
the case in reality. 
Despite the establishment of clearer decision-making structures (due to GAVI 
requirements), procedures were not necessarily more thorough. The decision-
making process for more recent GAVI-funded vaccines (e.g. pneumococcal and 
rotavirus) appear to be faster than that for the earlier Hib vaccine, where only 
Kenya applied as soon as the possibility arose (see Table 2). Compared to the 
deliberations about whether to apply for Hib vaccine funding, there were often 
fewer discussions about whether or not to apply for these more recent vaccines. 
It seemed that as the GAVI system became better understood and countries 
gained experience in developing applications, the decision to apply became 
more automatic. 
The adoption of the meningococcal vaccine in Mali differed from other GAVI-
supported vaccines. It involved the establishment of a partnership to support the 
development of the vaccine and required African Ministers of Health from 
meningitis-belt countries to commit to fast-track its adoption. In Mali, WHO was 
viewed as taking the lead in providing evidence of the safety and efficacy of the 
new vaccine and planning the introduction through region-wide vaccination 
campaigns.
Evidence
The importance of evidence – particularly of the incidence or burden of disease 
– was universally recognised. In countries with sufficient capacity to conduct 
their own studies, local findings were considered critical. Indeed, interviewees 
from several countries (Mali, Kenya and Bangladesh) reported that new 
vaccines would not be adopted unless local disease burden data were 
available. These tended to be countries with substantial epidemiological 
surveillance capacity. Countries lacking capacity were more willing to look at 
evidence from elsewhere. 
“There are capacity limitations of conducting such a [local] study and you 
should not wait, really, to have such a study for introduction of these 
vaccines. I mean regional data are more or less similar, and other 
evidences are also similar."  007, Ethiopia
WHO often played a key role in providing technical assistance and financing the 
collection of local surveillance data. 
Although most discussions of evidence focused on disease burden data, some 
interviewees also mentioned impact studies, particularly from previous vaccine 
introductions such as Hib vaccine. These were felt to provide evidence of the 
usefulness of vaccines generally, thus supporting decisions to adopt new 
vaccines. In countries where efficacy studies had taken place (e.g. South 
Africa), these were considered influential in getting the vaccine onto the 
decision-making agenda.
South Africa, Mali and Kenya reported conducting economic evaluations or 
cost-effectiveness studies to support their decisions. In South Africa, ‘rough’ 
analyses, rather than ‘rigorous, academic’ studies were done. In Guatemala, 
there was disagreement among interviewees about whether an economic 
evaluation had been conducted for the rotavirus vaccine and simply not 
communicated, or whether it had not been finished, or even started. 
Nevertheless, there was consensus that economic evidence had not informed 
the decision.
Drivers
The Importance of the Health Problem
The burden of disease and the political prioritisation of the vaccine-preventable 
disease were two key drivers influencing adoption decisions.
Disease burden was universally considered to be an important driver of 
decisions to adopt new vaccines. It also helped in selecting which vaccine to 
apply for, when, for example, GAVI offered more than one (e.g. pneumococcal 
and rotavirus vaccines). In Bangladesh, a number of disease burden studies 
were conducted before Hib vaccine was adopted; interviewees suggested that 
doubts about disease burden were one cause of the adoption delay. 
Some interviewees felt that where the disease was highly visible (e.g. 
pneumococcal in Kenya or meningococcal in Mali), there was less debate 
around whether to adopt the vaccine. 
Although the burden of disease was clearly necessary for adoption decisions, it 
was not generally sufficient; political prioritisation was arguably more influential. 
Immunisation was generally considered a high government priority; indeed in 
several countries (e.g. Mali and Cameroon) coverage was one of the National 
Health Strategy’s performance targets and in Kenya it was one of the 
President’s performance targets. Achieving the Millennium Development Goal 
(MDG) 4 (reducing child mortality) was noted as a key driver by interviewees in 
almost all countries. 
In both Guatemala and South Africa, interviewees reported political pressure on 
the Ministers of Health for a ‘good news’ story. In South Africa, lack of progress 
towards the MDGs (largely due to HIV, which the Minister would not address) as 
well as upcoming elections, were considered major incentives for the Minister to 
decide to adopt two vaccines at once.
Interim government and parliamentary elections were other major factors cited 
as delaying the Hib adoption decision in Bangladesh. 
Other criteria within the ‘importance of the health problem’ (e.g. ‘costs of the 
disease’) were rarely mentioned.
Vaccine Characteristics
Criteria such as vaccine efficacy or safety were mentioned only occasionally. A 
few interviewees mentioned the development of new vaccines as a driver of 
decision-making. In Kenya, interviewees explained that after the introduction of 
Hib vaccine, they were watching developments of a pneumococcal vaccine (as 
they believed that this would have a greater impact on pneumonia than Hib 
vaccination).
Programmatic Considerations
Programmatic issues, such as whether adoption was feasible, seemed to delay 
introductions rather than influence adoption decisions. Cold chain capacity 
issues were particularly noted. Several countries (e.g. Cameroon) upgraded 
their cold chain in preparation for GAVI applications or as part of introduction 
plans. Vaccine supply issues were only noted as affecting which pneumococcal 
vaccine to adopt, rather than the decision to adopt per se.
Acceptability
The acceptability of vaccination was high in all countries and therefore not 
mentioned as an influential factor affecting decisions. Although acceptability 
issues were raised by some stakeholders in Mali and Cameroon, they did not 
influence decisions.
Accessibility, Equity and Ethics
Accessibility and equity were not mentioned as a concern except in South Africa 
where the government was felt to be particularly sensitive to issues of 
inequalities. In this country, the availability of the vaccines in the private sector 
raised concerns about social inequity.
Financial/Economic Issues
There were four main financial/economic issues: the availability of funding, co-
financing, financial sustainability and cost-effectiveness or affordability.
In all five GAVI-eligible countries in the study, the availability of GAVI funding 
was a major – possibly the major - driver of adoption decisions. Many 
interviewees stated explicitly that without GAVI funding, the adoption of new 
vaccines would not be possible. 
In Bangladesh it seemed clear that GAVI’s funding priorities trumped the 
national priorities of rubella and hepatitis B birth dose, so pneumococcal and 
measles (second dose) became the next candidates for adoption (applied for in 
2011). 
In Guatemala, interviewees did not believe financial considerations influenced 
the rotavirus vaccine decision. In South Africa, the fact that the Ministry of 
Finance had money available that they were willing to spend on new vaccines 
was a key driver of the decision. Financial sustainability was not considered as 
a hindrance in either of these countries.
In order to receive GAVI funding, countries are required to co-finance a 
proportion of the costs, with annual increments. Interviewees gave a sense that 
the importance of co-financing arrangements, as a disincentive to adoption, had 
diminished as more GAVI-funded introductions occurred. It appeared that as 
countries became accustomed to the co-financing requirement, there was less 
concern and discussion about whether the adoption would be affordable. Some 
felt that co-financing was not a major concern since the amount required was 
small compared to the overall cost.
“…because in terms of cost, when they look at it, the vaccine cost, it’s 
about  $30 if not more, it should be more than $30 per dose, yeah. So, 
and say in Europe or North America that’s the cost, so when you are 
being asked to pay $0.15 per dose, it’s just like peanuts.” 003, Kenya
As mentioned above, in some cases interviewees implied that the decision to 
apply for GAVI funding was made before the co-financing arrangement had 
been agreed with the Ministry of Finance. However, in several countries (e.g. 
Bangladesh) the Ministry of Health had authority over its own budget, so 
approval from the Ministry of Finance was perceived as a formality only.
Among the GAVI-eligible countries, there were mixed opinions about whether 
financial sustainability was a concern, or whether it had been discussed prior to 
the decision to apply for GAVI funding. Although there were hopes that vaccine 
prices would fall over time, several noted that the anticipated decline in the 
pentavalent vaccine price had been less than expected. Some interviewees 
worried that countries were ‘grabbing’ funding opportunities without considering 
the long-term consequences, particularly as the number of vaccines being co-
financed increased.
“If the WHO - and it’s often GAVI, but they’re all the same to me because they 
work together - make an offer, all countries jump on it but without really 
considering all the consequences”  010, Mali
In Bangladesh, interviewees were clear that they did not view financial 
sustainability in terms of government contributions. Instead they considered 
where external funding could be obtained in future. 
Although some interviewees did mention considering the vaccines’ value for 
money, they rarely used economic evaluations to estimate this. A minority 
mentioned the issue of the vaccine’s affordability, price or systems costs. Where 
systems costs were mentioned, discussions were generally held after the 
decision to apply for GAVI funding, rather than as an issue influencing the 
decision.
Impact of Vaccination
The potential impact of the new vaccine on health outcomes (notably child 
mortality) was particularly mentioned by interviewees in Cameroon, Ethiopia, 
Mali and South Africa. However it was difficult to differentiate comments about 
the political priority of achieving MDG4, or reducing child mortality, and 
comments about the vaccines’ health impact; there seemed to be substantial 
overlap between these two criteria. 
Other impact criteria, such as the impact on non-health outcomes, effect of co-
administration or risks of serotype replacement, were only occasionally 
mentioned. They were more often considered during introduction planning, after 
the decision to adopt had been made.
Consideration of Alternative Interventions 
Alternative interventions were rarely mentioned. In Ethiopia, some interviewees 
noted that Ministry of Health staff were initially resistant to the introduction of 
community-based pneumonia treatment, an intervention perceived to being 
‘pushed’ by non-governmental sources. This enhanced the appeal of a 
pneumococcal vaccine.
With regards to rotavirus, occasionally the issue of improvements in hygiene, 
water supply and sanitation were raised as an alternative to vaccination, but 
these did not appear to have been a significant consideration.
Other Drivers
Countries reported that advocacy activities by international agencies, such as 
the WHO, played a key role in setting the agenda at country level and in 
supporting the decision-making process. 
A few interviewees felt that new vaccine introductions in other (often 
neighbouring) countries helped to promote adoption in their country, although 
most felt that this had little influential effect.
The availability of the new vaccine in the private health sector was not 
considered influential, since such a small proportion of the population could 
access these services. The only exception was in South Africa, as mentioned 
above. 
Discussion
The strength of this study lies in its comparison of decision-making across 
seven countries, drawing on interviews with 94 key informants, and in its clear 
analytical framework. A possible limitation was that the sensitive nature of 
decision-making may have led to some acquiescence bias and assumptions 
about the process. However many interviewees were honest about 
shortcomings in the decision-making process and by interviewing a range of 
key informants, it was possible to triangulate and identify areas particularly 
vulnerable to acquiescence bias or idealistic assumptions.
The underlying driver for adoption decisions in GAVI-eligible countries was the 
desire to seize windows of opportunity for funding. By contrast, in South Africa 
and Guatemala, the decision-making process appeared to be more rooted in 
internal and political dynamics.
Our results confirm that vaccination is a political issue in non GAVI- as well as 
GAVI-eligible countries. Other studies have also highlighted the importance of 
political factors in vaccine adoption decisions (Bryson et al., 2010, Haas et al., 
2009, Druce et al., 2006, Brooks et al., 1999). Hence, deciding to adopt a new 
vaccine is not simply a technical, evidence-informed decision but rather an 
example of the craft of policy-making (Shiffman and Smith, 2007). 
Consistent with previous findings, the burden of disease was another important 
factor (Druce et al., 2006, Munira and Fritzen, 2007). Although local evidence 
was considered critical for decision-making in countries where it was available, 
those lacking local data accepted the need to rely on evidence from elsewhere. 
A preference for local evidence has been reported elsewhere, both for vaccine 
decision-making and other areas of health policy (Woelk et al., 2009, Burchett, 
2010).
There appears to have been a very effective global advocacy strategy focused 
particularly on Ministers. This may have influenced the extent to which policy 
decisions were evidence-informed. In the GAVI-eligible countries, the decision-
making process appeared to be speeding up, with less consideration of 
whether to adopt compared to earlier vaccine adoptions (World Health 
Organization, 2008, Lairumbi et al., 2008, Shearer et al., 2010, Levine et al., 
2011). This may be because understandings of and confidence in GAVI have 
increased following earlier experiences. It also suggests that, whilst GAVI has 
led to the establishment of more formal national procedures, at the same time it 
may have diminished the thoroughness of the decision-making process. There 
appeared to be little consideration of the financial implications of adoption (both 
in terms of co-financing and financial sustainability), particularly when 
compared to earlier GAVI-funded adoptions (Gordon et al., 2011, Weber, 2004). 
This is a particular concern given increasing immunisation budgets and more 
costly new vaccines (Lydon et al., 2008, Zuber et al., 2011, McQuestion et al., 
2011). Other studies have noted a lack of capacity to conduct and interpret 
economic evaluations in low- and middle-income countries, which may also 
help explain the lack of consideration of financial and economic issues (Gordon 
et al., 2011, Jauregui et al., 2011).
The fact that the desire to seize the opportunity of GAVI funding may stifle a 
thorough consideration of the advantages and disadvantages of new vaccine 
adoption supports arguments made in other studies, that donors risk ‘taking 
over’ decision-making (Brooks et al., 1999, Druce et al., 2006, Lairumbi et al., 
2008, Weber, 2004). 
In summary, the main drivers influencing vaccine adoption decisions were the 
availability of funding, political prioritisation of vaccination or the vaccine-
preventable disease and the burden of disease. Other factors did not appear to 
be influential and if they were considered, it was generally once the decision 
had been made. The fact that programmatic issues were not key factors in the 
adoption process raises questions about the capacity of the vaccination 
programme to absorb the new vaccine(s). The current study found that the 
framework developed from existing published decision-making frameworks was 
more comprehensive than the actual factors that influenced vaccine adoption 
decision-making in the study countries.  
Conclusion
Decisions to adopt new vaccines are, by nature, political. However, it is clearly 
important that evidence is used to inform these decisions and the feasibility and 
sustainability of new vaccine introductions are considered. Although GAVI 
procedures have established more formality in decision-making, they have not 
resulted in consideration of all relevant factors. It seems that, as GAVI-eligible 
countries became familiar with GAVI procedures, so their questioning about 
whether they should apply for funding diminished. The lack of consideration of 
financial factors and the feasibility of vaccine adoption is concerning. They have 
implications not only for GAVI, but also for other international initiatives, in terms 
of how they engage with national decision-making processes and the extent to 
which they encourage evidence-informed decision-making.
This study provides much needed evidence about the nature of vaccine 
decision-making processes and particularly challenges assumptions held about 
them (e.g. that they are formal, technical and consultative). Understanding these 
processes is critical for developing strategies to encourage evidence-informed 
decision-making about new vaccine adoptions. The potential for international 
initiatives to encourage evidence-informed decision-making should be realised, 
not assumed.
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